ReviewOncoTargets and therapy2026
Advances in Liquid Biopsy for Precision Oncology: Applications, Challenges, and Future Directions in Clinical Laboratories.
Review in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsy has emerged as a revolutionary, minimally invasive approach in precision oncology, enabling dynamic molecular profiling of tumors through analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and other biomarkers in body fluids. Focusing specifically on recent advances from 2023 to 2026, this review provides a laboratory-centered critical synthesis addressing the core operational questions for clinical implementation: which liquid biopsy platform should be selected for specific analytes and clinical intents, under what pre-analytical and analytical constraints, and with what quality-control and clinical utility standards. Key technological developments include highly sensitive next-generation sequencing (NGS) with unique molecular identifiers (UMIs), digital droplet PCR (ddPCR), multi-omics integration, and artificial intelligence-assisted interpretation, which have improved detection sensitivity to ultra-low variant allele frequencies. Major clinical applications encompass multi-cancer early detection (MCED), companion diagnostics, real-time treatment monitoring, minimal residual disease (MRD) assessment, and resistance mutation tracking. These tools often provide earlier insights than imaging and better capture tumor heterogeneity. Compared with tissue biopsy, liquid biopsy offers advantages in repeatability, speed, and systemic representation, though challenges remain in sensitivity for early-stage disease, standardization, cost-effectiveness, and implementation in grassroots hospitals. Future directions emphasize multi-omics, AI, and automated workflows to enhance its role across the cancer continuum. This review highlights practical recommendations for clinical laboratories, positioning liquid biopsy as a cornerstone of personalized, proactive oncology care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.